Access cutting-edge rsv infection treatment through this clinical trial at a research site in Washington Dc. Study-provided care at no cost to qualified participants.
Access rsv infection specialists in Washington Dc at no cost
This study follows strict safety protocols and ethical guidelines
All study-related rsv infection treatment provided free
The overarching hypothesis of the ARRC trial is that administration of Azithromycin (AZM) during acute, Respiratory Syncytial Virus (RSV)-induced respiratory failure will be beneficial, mediated through the matrix metalloproteinase (MMP)-9 pathway.
Sponsor: University of Alabama at Birmingham
Check if you qualify for this rsv infection clinical trial in Washington Dc, DC
If you're searching for rsv infection treatment options in Washington Dc, DC, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Washington Dc research site is actively enrolling participants for this clinical trial. You'll receive care from experienced rsv infection specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.